Table 1.
Patient and transplant characteristics
| Characteristic | Value |
|---|---|
| Total no. of patients | 21 |
| Age, median (range), y | 56 (22-72) |
| Sex | |
| Male | 12 (57%) |
| Female | 9 (43%) |
| Diagnosis | |
| AML | 18 (86%) |
| MDS/MPN | 2 (9%) |
| ALL | 1 (5%) |
| Donor status | |
| MRD | 7 (33%) |
| MUD | 13 (62%) |
| 7/8 MUD | 1 (5%) |
| IM-TMI regimen | |
| RIC (Flu-mel-TMI), 6 Gy | 5 (24%) |
| RIC (Flu-mel-TMI), 9 Gy | 10 (48%) |
| RIC (Flu-mel-TMI), 12 Gy | 6 (28%) |
| Disease status before SCT | |
| CR2 | 6 (29%) |
| CR3 | 4 (19%) |
| Active disease | 11 (52%) |
| Duration of remission of first SCT, median (range), d | 355 (55-1494) |
| Time from last relapse to protocol therapy, median (range), d | 206 (85-2534) |
| HCT-CI, median (range) | 1 (0-6) |
| Karnofsky performance status score, median (range) | 90 (70-100) |
ALL, acute lymphoblastic leukemia; Flu-mel, fludarabine-melphalan; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor.